Fellowship · Sacramento, CA
Sponsored by University of California Davis Health
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 571 citations · Primo Nery Lara
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 226 citations · Mamta Parikh
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 168 citations · Primo Nery Lara
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 259 citations · Mamta Parikh
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet (London, England) · 2021 · 241 citations · Primo Nery Lara
Global health 2050: the path to halving premature death by mid-century.
Lancet (London, England) · 2024 · 85 citations · Shuchi Anand
Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology.
Kidney international · 2025 · 44 citations · Shuchi Anand
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
The Lancet. Oncology · 2022 · 184 citations · Primo Nery Lara